Study of a new drug combination to treat Leukemia

Phase 1

• Conditions: Chronic Lymphocytic Leukaemia; MedDRA version: 18.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 18.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); MedDRA version: 18.1Level: HLGTClassification code 10024324Term: LeukaemiasSystem Organ Class: 10005329 - Blood and lymphatic system disorders; MedDRA version: 18.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disorders; MedDRA version: 18.1Level: HLTClassification code 10024295Term: Leukaemias chronic lymphocyticSystem Organ Class: 10005329 - Blood and lymphatic system disorders; MedDRA version: 18.1Level: PTClassification code 10008959Term: Chronic lymphocytic leukaemia (in remission)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]

• Registration Number: EUCTR2008-004932-19-BE
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-11-03
• Study Completion: 2009-07-28
• Last Update Posted: 10 August 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 0

Inclusion Criteria

1.Diagnosis of CLL defined by:
• Circulating lymphocytes =5,000/µL
AND
• Flow cytometry confirmation of immunophenotype with CD5, CD19, CD20,
CD23, CD79b, and surface Ig prior to Visit 2
Lymphocytosis with less than 5,000/µL B lymphocytes displaying the CLLimmunophenotype but in the absence of other features of a B-cell
lymphoproliferate disorder (lymphadenopathy, organomegaly, cytopenias,
disease-related symptoms) is defined as monoclonal B-lymphocytosis (MBL), not
CLL.

2.Considered inappropriate for fludarabine-based therapy, for reasons that include, but not limited to, advanced age or presence of co-morbidities

3. Active disease and indication for treatment based on modified NCI-WG guidelines [Hallek, 2008] defined by presenting at least any one of the following conditions:
•Evidence of progressive marrow failure as manifested by development or worsening of anemia and/or thrombocytopenia
•Massive (i.e. > 6cm below the left costal margin) or progressive or symptomatic splenomegaly
•Massive nodes (i.e. > 10cm in longest diameter) or progressive or symptomatic lymphadenopathy
•Progressive lymphocytosis with an increase of more than 50% over a two month period or an lymphocyte doubling time of less than 6 months. In patients with initial blood lymphocyte counts of less than 30x10^9/L, lymphocyte doubling time should not be used as a single parameter to define a treatment indication. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL (eg, infections) should be excluded.
•A minimum of any one of the following disease-related symptoms must be present:
a) Unintentional Weight loss =10% within the previous six months
b) Fevers > 100.5oF (38.0oC) for = 2 weeks without evidence of infection
c) Night sweats for more than 1 month without evidence of infection

4.Not been previously treated for CLL (prior autoimmune hemolytic anemia treatment permitted)

5.ECOG Performance Status of 0-2

6.Life expectancy of at least 6 months

7.Age = 18 years

8.Signed written informed consent prior to performing any study-specific procedures

French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 148
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 269

Exclusion Criteria

1.Prior immuno- or chemotherapy for CLL or small lymphocytic lymphoma (SLL) with any agent except corticosteroids used to treat autoimmune hemolytic anemia

2.Previous autologous or allogeneic stem cell transplantation

3.Active autoimmune hemolytic anemia (AIHA) requiring corticosteroid therapy > 100mg equivalent to hydrocortisone, or chemotherapy

4.Known transformation of CLL (e.g. Richter)

5.Known CNS involvement of CLL

6.Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C.

7.Other past or current malignancy. Subjects who have been free of malignancy for at least 5 years, or have a history of completely resected non-melanoma skin cancer, or successfully treated in situ carcinoma are eligible.

8.Clinically significant cardiac disease including unstable angina, acute myocardial infarction within 6 months prior to Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities

9.History of significant cerebrovascular disease or event with significant symptoms or sequelae

10.Glucocorticoid use, unless given in doses = 100mg/day hydrocortisone (or equivalent dose of other glucocorticoid) for <7 days for exacerbations other than CLL (e.g. asthma)

11.Known HIV positive

12.Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded. If HBV DNA is negative, subject may be included but must undergo HBV DNA monitoring (see Section 6.3.4). Prophylactic antiviral therapy may be initiated at the discretion of the investigator.

13.Screening laboratory values:

•Creatinine > 2.0 times upper normal limit (unless normal creatinine clearance)
•Total bilirubin > 2.0 times upper normal limit (unless due to liver involvement of CLL)
•alanine transaminase (ALT) > 3.0 times upper normal limit (unless due to liver involvement of CLL)

14.Previous treatment or known or suspected hypersensitivity to ofatumumab that in the opinion of the investigator or medical monitor is a contraindication to their participation in the present study

15.Treatment with any known non-marketed drug substance or experimental therapy within 5 terminal half lives or 4 weeks prior to Visit 1, whichever is longer, treatment with any anti-CD20 monoclonal antibody within 3 months of Visit 1, or participation in any other interventional clinical study. Note: Participation in any other interventional clinical study after disease progression during post PD-followup is permitted.

16.Known or suspected inability to comply with study protocol

17.Lactating women, women with a positive pregnancy test at Visit 1 or women (of childbearing potential) as well as men with partners of childbearing potential, who are not willing to use adequate contraception from study start through one year following last treatment dose. Adequate contraception is defined as abstinence, oral hormonal birth control, hormonal birth control injections, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is sole p

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: The primary objective is to evaluate progression-free-survival of ofatumumab added to chlorambucil therapy vs. chlorambucil therapy for the treatment of previously untreated (frontline) CLL.;Secondary Objective: Secondary objectives are to evaluate clinical benefit, safety, tolerability, changes in patient reported outcome measures (PRO) and pharmacokinetics of subjects treated with ofatumumab added to chlorambucil.<br>;Primary end point(s): • Progression free survival (PFS), defined as the interval between randomization until disease progression or death.;Timepoint(s) of evaluation of this end point: Anticipated: 26-May-2011

Secondary Outcome Measures

Name	Time	Method
Secondary end point(s): Overall response rate, Overall survival, Changes in patient reported outcome measures, Number of complete remissions, Time to response, duration of response, Time to progression, time to next therapy, Improvement of ECOG PS, Improvement in B-symptoms, Incidence and severity of AEs, SAEs and other safety parameters,Human Anti Human Antibodies (HAHA), CIRS;Timepoint(s) of evaluation of this end point: At primary endpoint analysis (26-May-2011) and at end of study (16-Jun-2022)